Literature DB >> 31690822

ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.

Arina Riabinska1, Daria Lehrmann2, Ron Daniel Jachimowicz2, Gero Knittel2, Christian Fritz2, Anna Schmitt2, Aenne Geyer2, Carola Heneweer3, Maike Wittersheim4, Lukas P Frenzel2,5, Alessandro Torgovnick2,5, Janica Lea Wiederstein5, Claudia Maria Wunderlich6, Monika Ortmann4, Arlette Paillard7, Wilhelm Wößmann8, Arndt Borkhardt9, Stefan Burdach10, Martin-Leo Hansmann11, Andreas Rosenwald12, Sven Perner13, Gita Mall14, Wolfram Klapper15, Andrea Merseburg16, Marcus Krüger5, Holger Grüll3, Thorsten Persigehl3, Frank Thomas Wunderlich6, Martin Peifer17,18, Olaf Utermöhlen7,17,19, Reinhard Büttner4,17, Filippo Beleggia2, Hans Christian Reinhardt20,21,22.   

Abstract

The proximal DNA damage response kinase ATM is frequently inactivated in human malignancies. Germline mutations in the ATM gene cause Ataxia-telangiectasia (A-T), characterized by cerebellar ataxia and cancer predisposition. Whether ATM deficiency impacts on tumor initiation or also on the maintenance of the malignant state is unclear. Here, we show that Atm reactivation in initially Atm-deficient B- and T cell lymphomas induces tumor regression. We further find a reduced T cell abundance in B cell lymphomas from Atm-defective mice and A-T patients. Using T cell-specific Atm-knockout models, as well as allogeneic transplantation experiments, we pinpoint impaired immune surveillance as a contributor to cancer predisposition and development. Moreover, we demonstrate that Atm-deficient T cells display impaired proliferation capacity upon stimulation, due to replication stress. Altogether, our data indicate that T cell-specific restoration of ATM activity or allogeneic hematopoietic stem cell transplantation may prevent lymphomagenesis in A-T patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31690822     DOI: 10.1038/s41375-019-0618-2

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.

Authors:  Anne C Wilke; Carmen Doebele; Alena Zindel; Kwang Seok Lee; Sara A Rieke; Michele Ceribelli; Federico Comoglio; James D Phelan; James Q Wang; Yana Pikman; Dominique Jahn; Björn Häupl; Constanze Schneider; Sebastian Scheich; Frances A Tosto; Hanibal Bohnenberger; Philipp Stauder; Frank Schnütgen; Mikolaj Slabicki; Zana A Coulibaly; Sebastian Wolf; Kamil Bojarczuk; Björn Chapuy; Christian H Brandts; Philipp Stroebel; Caroline A Lewis; Michael Engelke; Xincheng Xu; Hahn Kim; Thanh Hung Dang; Roland Schmitz; Daniel J Hodson; Kimberly Stegmaier; Henning Urlaub; Hubert Serve; Clemens A Schmitt; Fernando Kreuz; Gero Knittel; Joshua D Rabinowitz; Hans Christian Reinhardt; Matthew G Vander Heiden; Craig Thomas; Louis M Staudt; Thorsten Zenz; Thomas Oellerich
Journal:  Blood       Date:  2022-01-27       Impact factor: 25.476

Review 2.  Update on DNA-Double Strand Break Repair Defects in Combined Primary Immunodeficiency.

Authors:  Mary A Slatter; Andrew R Gennery
Journal:  Curr Allergy Asthma Rep       Date:  2020-07-09       Impact factor: 4.806

Review 3.  Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma.

Authors:  Paul J Bröckelmann; Mathilde R W de Jong; Ron D Jachimowicz
Journal:  Cells       Date:  2020-10-14       Impact factor: 6.600

4.  DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells.

Authors:  Zachary J Waldrip; Lyle Burdine; David K Harrison; Ana Clara Azevedo-Pouly; Aaron J Storey; Olivia G Moffett; Samuel G Mackintosh; Marie Schluterman Burdine
Journal:  J Biol Chem       Date:  2021-09-23       Impact factor: 5.157

Review 5.  Synthetic Lethality in Cancer Therapeutics: The Next Generation.

Authors:  Jeremy Setton; Michael Zinda; Nadeem Riaz; Daniel Durocher; Michal Zimmermann; Maria Koehler; Jorge S Reis-Filho; Simon N Powell
Journal:  Cancer Discov       Date:  2021-04-01       Impact factor: 39.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.